The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesions of the head and neck.
 
Dong Moon Shin
No Relationships to Disclose
 
Jonathan Jay Beitler
No Relationships to Disclose
 
Mark El-Deiry
No Relationships to Disclose
 
Conor Ernst Steuer
Honoraria - Merck
Consulting or Advisory Role - Abbvie; ARMO BioSciences; BerGenBio
Research Funding - Vaccinex
 
Amy Y. Chen
No Relationships to Disclose
 
Harry Micael Baddour
No Relationships to Disclose
 
Zhuo Georgia Chen
No Relationships to Disclose
 
Steve Roser
No Relationships to Disclose
 
Kelly R. Magliocca
No Relationships to Disclose
 
Mihir Patel
No Relationships to Disclose
 
Christopher C Griffith
No Relationships to Disclose
 
Adam Klein
No Relationships to Disclose
 
Taofeek Kunle Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; G1 Therapeutics; Lilly; Lilly; MedImmune; Novartis; PharmaMar; Sandoz; Seagen; Takeda
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Corvus Pharmaceuticals; G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst); United Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)
Other Relationship - Roche/Genentech
 
Fadlo Khuri
No Relationships to Disclose
 
Sreenivas Nannapaneni
No Relationships to Disclose
 
Nabil F. Saba
Honoraria - Bristol-Myers Squibb; Lilly; Merck; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck; Pfizer
Research Funding - Bristol-Myers Squibb; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Pfizer